Drug Type Gene editing |
Synonyms CXR 101, CXR101 |
Target |
Action modulators |
Mechanism Nrf2 modulators(Nuclear factor erythroid 2-related factor 2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Preclinical | United States | 01 Sep 2025 |





